UBS Global Life Sciences Conf

RNS Number : 6976D

Oxford Biomedica PLC

18 September 2008

 



For Immediate Release	18 SEPTEMBER 2008

OXFORD BIOMEDICA TO PRESENT AT UBS GLOBAL LIFE SCIENCES CONFERENCE

Oxford, UK - 18 September 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces that Nick Woolf, Oxford BioMedica's Chief Business Officer, will present a Company update at the UBS Global Life Sciences Conference in New York City on Wednesday, 24 September 2008 at 4.00pm BST (11.00am ET).

The presentation will be webcast live and may be accessed under the investors section of the Company's website, www.oxfordbiomedica.co.uk. The presentation will also be available for replay.

-Ends-

For further information, please contact:
Oxford BioMedica plc:  John Dawson, Acting Chief Executive Officer Nick Woolf, Chief Business Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Claire Mosley/ Holly Griffiths/ Katja Stout College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. 

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax®, an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. 

Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

NRAQDLFFVKBFBBB